PHC Group Releases Newly Revised Mid-Term Plan, the “Value Creation Plan,” Outlining Changes for FY2025 to Accelerate Growth by Advancing Value-Based Healthcare
16.11.2022 09:30:00 EET | Business Wire | Press release
PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: Shoji Miyazaki, hereafter PHC Group) announces the release of its newly revised Mid-term Plan, the “Value Creation Plan”*1 for FY2022 to FY2025. The primary update in this plan is the introduction of new business growth areas that will enable PHC Group to advance value-based healthcare globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115005183/en/
PHC Group’s Growth Areas (Graphic: Business Wire)
Our Value Creation Strategy Focuses on Realizing “Value-Based Healthcare”
Since the original Mid-term Plan was released in June 2021, PHC Group has initiated new commercial partnerships, expanded investments in our core business domains and completed its listing on the Tokyo Stock Exchange’s First Section (current Prime market) in October 2021. At the same time, increasing healthcare costs and disparities in access to healthcare, caused by issues like geographic location and income, continue to be critical challenges around the world. In light of these challenges, PHC Group has updated its global business strategy to focus on contributing to “Value-Based Healthcare,” a healthcare delivery model that seeks to maximize healthcare outcomes for patients based on their individual needs, which can lead to better care as well as improved cost-effectiveness.
Specifically, PHC Group will seek to strengthen its three core business domains while leveraging synergies among those businesses to target three new growth areas:
Strategy on Foundation (Core Business Domains)
- Diabetes Management: PHC Group will expand new business opportunities for blood glucose monitoring systems (BGM) in emerging markets and enhance growth business such as continuous glucose monitoring system (CGM).
- Healthcare Solutions: The Medicom (healthcare IT) business in Japan will seek to capitalize on demand from the shift to cloud-based electronic medical record (EMR) systems and Japanese government-led policies. The LSI Medience (clinical testing services and diagnostic reagents) business will enhance cancer and genetic testing and boost clinical trials and point-of-care testing (POCT) businesses outside of Japan.
- Diagnostics & Life Sciences: The PHCbi (biomedical) business will develop new products with energy-saving performance and internet of things (IoT) technology, and also optimize its global operations in development and manufacturing. The Epredia (anatomical pathology) business will seek to increase its market share by upgrading product quality and tapping into sales channels by region and segment used by PHC Group Business.
Strategy for Growth
- Personalized Testing and Diagnostic Solutions: The diabetes management business, including Ascensia and PHC IVD, will promote sales of its innovative CGM and develop POCT technologies.
- Digital Health Solutions: Medicom and LSI Medience will integrate their healthcare management businesses including annual health check programs to advance health support including preventive medicine for individuals. They will advance solutions that assist the workflow for healthcare professionals such as administrative support services efficiently managed by AI. To contribute to reducing healthcare costs and enhancing treatments, PHC Group will work to integrate and analyze health data.
- Advanced Therapy Development Solutions: The Epredia and PHCbi businesses will leverage one another’s customer networks in pharmaceutical companies to expand sales globally for both brands. Expanded product portfolios will include new equipment for cell metabolism analysis and anatomical pathology, and high-quality, high-speed models for diagnostics using AI will be developed for hospitals.
Revised Financial Targets
Through this Value Creation Plan, PHC Group is targeting 420 bn/JPY in revenue and 56 bn/JPY in operating profit:
|
FY2021 Actual |
FY2025 Target*2 |
CAGR | 2021-2025 |
|
| Revenue | 340.5bn | 420bn |
+5.4% |
| Operating Profit | 8.2bn | 56bn |
+62% |
| (Margin) |
(2%) |
(13%) |
20% if impairment |
| Impairment of | is not included | ||
| 18.4bn/JPY of Epredia | |||
| business included | |||
| Cash-based | 24.8bn | 49bn |
+19% |
| net income | |||
| EBITDA | 57.7bn | 87bn |
+11% |
| Adjusted EBITDA | 71.9bn | 87bn |
+4.9% |
| Reference | |||
| Assumed Exchange Rate | |||
|
$ |
112JPY | 130JPY | |
|
€ |
130JPY | 132JPY | |
With this combination of foundational business and new growth areas, PHC Group’s newly revised Value Creation Plan will help the company advance its corporate mission of “contributing to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people.”
*1 Website on our “Value Creation Plan”: www.phchd.com/global/about/vcp
*2 Based on current business portfolio
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TOKYO Prime 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries include PHC Corporation, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., and LSI Medience Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, diagnostics and life sciences. PHC Group’s consolidated net sales in FY2021 were JPY 340 billion with global distribution of products and services in more than 125 countries.
www.phchd.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005183/en/
Contact information
Media Contact:
Julia Cottrill
Hiroko Arai
Investor Relations & Corporate Communications Group
PHC Holdings Corporation
TEL: +81-3-6778-5311
Email:
phc-pr@gg.phchd.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Energy Announces 6,000 bpd Group III Base Oil Expansion Project24.6.2026 17:00:00 EEST | Press release
Vertex Energy, Inc. (“Vertex” or the “Company”) today announced it is advancing a project at its Mobile, Alabama refinery to produce crude-derived conventional Group III base oils through the Company’s existing hydrocracker and related processing infrastructure, providing lubricant manufacturers and blenders with an additional domestic source of high-quality Group III supply. The project is designed to add an incremental 6,000 barrels per day of conventional Group III production capacity and support production of 4 cSt, 6 cSt, and 8 cSt Group III base oils using an existing crude-derived hydrocracked vacuum gas oil stream produced at the Company’s Mobile, Alabama refinery. Combined with the Company’s existing re-refined Group III base oil production, this additional capacity is expected to make Vertex the leading Group III producer in North America. Vertex has completed preliminary design work and has procured a high-pressure lubricants hydrotreating unit. The Company plans to start pr
Taktile Secures $110M in Goldman Sachs-led Series C to Power AI Transformation in Financial Institutions24.6.2026 16:30:00 EEST | Press release
Taktile, the leader in AI transformation for financial institutions, today announced its $110 million Series C fundraise. Growth Equity at Goldman Sachs Alternatives led the round, with participation from Balderton Capital, Index Ventures, Tiger Global, Y Combinator, and Dig Ventures. Taktile Fast Facts Taktile enables banks and insurers to transform into AI-native organizations that are increasingly powered by autonomous agents. Demand for Taktile accelerated in 2025, as AI models became capable of automating high-stakes decisions that previously required hours of manual work—from underwriting business loans and assessing claims to catching financial crime. Customers automate and optimize decisions with Taktile by combining its financial services expertise and product built for sector-specific AI use cases. One of the world’s largest insurers is running multiple use cases on Taktile, with projected cost efficiencies of over $90M in claims processing alone. Taktile’s team has a proven
New MetLife Study Reveals a 72% “Confidence Gap” in Ability to Recover from Life's Setbacks24.6.2026 16:25:00 EEST | Press release
A new multinational study from MetLife reveals a striking “confidence gap”: while most adults describe themselves as resilient, their confidence drops by 72% when faced with real-life setbacks. The Confident Pathways Report, conducted across the United States, United Kingdom, Japan, and Mexico, was designed to better understand how confidence is built and sustained throughout life. The findings underscore the role of opportunity, preparedness, and support in building confidence - factors that help people navigate uncertainty, recover from setbacks and pursue their goals. At a time when soccer is bringing people and communities together around the world, the findings also highlight how early childhood experiences such as sports, education, and mentorship can help foster resilience and gain confidence from a young age. Key findings across the four countries surveyed include: Confidence drops by 72% when adults consider their ability to recover from setbacks. Respondents were far more lik
StatLab Launches CytoPath Disc, Advancing Standardized Cell Block Preparation Worldwide24.6.2026 16:08:00 EEST | Press release
StatLab Medical Products, a leading global developer and manufacturer of pathology supplies and equipment, today announced the global launch of the CytoPath Disc, an innovative cell block preparation technology designed to standardize and simplify cell block preparation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624368623/en/ Developed as an alternative to traditional cell block methods, which convert concentrated cells suspended in fluid into a paraffin-embedded format for slide-based evaluation, the patent‑pending CytoPath Disc offers a more streamlined and efficient approach. The CytoPath Disc absorbs concentrated cells within a simple, sponge-like matrix, which is then processed, embedded, stained, and sectioned using standard histology workflows. Traditional cell block preparation methods often present challenges in achieving consistent results due to complex procedures, as well as the need for additional equipm
TensorX Launches With €8M Seed Funding Round Led by Darius Cubed Ventures for Bet on European Sovereign AI Infrastructure With Plans to Deploy up to €100M in NVIDIA Blackwell GPUs24.6.2026 16:07:00 EEST | Press release
A team of Irish founders has committed €8 million to Nvidia Blackwell GPUs, including the latest B300 chips, to launch TensorX, a sovereign AI inference platform designed for Europe's AI builders, trusted by regulated industries and already generating revenue from paying customers. The company was founded by Shane Morton, is part of the NVIDIA Inception program and is partnering with Dell on sourcing GPU hardware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528791384/en/ (From left to right): Craig Donnelly, Shane Morton, Nicole Morton, Tim Grant At a time when enterprises are racing to adopt artificial intelligence but most remain unwilling to let their data leave European jurisdiction, TensorX offers high-performance inference with zero data retention, running entirely on dedicated hardware in Dublin and Helsinki. TensorX is also in advanced talks around a financing facility to further expand its European footprint,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom